Education
About Us
Working with TipRanks
Follow Us
Sagimet Biosciences, Inc. Class A (SGMT)
NASDAQ:SGMT
SGMT Stock Chart & Stats
$5.52
-$0.58(-10.41%)
At close: 4:00 PM EST
$5.52
-$0.58(-10.41%)
Day’s Range― - ―
52-Week Range$1.73 - $11.41
Previous CloseN/A
Volume1.06M
Average Volume (3M)499.14K
Market Cap
$171.13M
Enterprise Value$106.13M
Total Cash (Recent Filing)$116.69M
Total Debt (Recent Filing)$115.00K
Price to Earnings (P/E)―
Beta2.97
Next Earnings
Mar 30, 2026EPS Estimate
-0.42Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.40
Shares Outstanding31,001,108
10 Day Avg. Volume259,182
30 Day Avg. Volume499,140
Financial Highlights & Ratios
PEG Ratio0.59
Price to Book (P/B)0.91
Price to Sales (P/S)0.00
P/FCF Ratio-3.32
Enterprise Value/Market Cap0.62
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-1.74
Forecast
1Y Price Target
$28.57Price Target Upside417.57% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-1.94
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Acne Franchise And CommercializationStrong Phase III data from partner Ascletis for denifanstat, coupled with plans to initiate a Phase 2 trial for TVB‑3567 in moderate‑to‑severe acne, expands commercial opportunity in a sizable acne market.
Clinical DevelopmentPhase I pharmacokinetic results showed the denifanstat–resmetirom combination was generally well tolerated with no safety signals or discontinuations, supporting advancement to a Phase 2 study in patients with advanced MASH.
Intellectual Property And PartnershipsA global license agreement with TAPI for an innovative resmetirom API reduces potential intellectual property obstacles and enables development of a co‑formulated fixed‑dose combination to support pivotal studies.
Bears Say
Analyst CredibilityA disclosed conflict of interest at a covering firm may undermine confidence in its research and could damp investor sentiment until independent analysis confirms results.
Sagimet Biosciences, Inc. Class A News
SGMT FAQ
What was Sagimet Biosciences, Inc. Class A’s price range in the past 12 months?
Sagimet Biosciences, Inc. Class A lowest stock price was $1.73 and its highest was $11.41 in the past 12 months.
What is Sagimet Biosciences, Inc. Class A’s market cap?
Sagimet Biosciences, Inc. Class A’s market cap is $171.13M.
When is Sagimet Biosciences, Inc. Class A’s upcoming earnings report date?
Sagimet Biosciences, Inc. Class A’s upcoming earnings report date is Mar 30, 2026 which is in 79 days.
How were Sagimet Biosciences, Inc. Class A’s earnings last quarter?
Sagimet Biosciences, Inc. Class A released its earnings results on Nov 13, 2025. The company reported -$0.4 earnings per share for the quarter, missing the consensus estimate of -$0.386 by -$0.014.
Is Sagimet Biosciences, Inc. Class A overvalued?
According to Wall Street analysts Sagimet Biosciences, Inc. Class A’s price is currently Undervalued.
Does Sagimet Biosciences, Inc. Class A pay dividends?
Sagimet Biosciences, Inc. Class A does not currently pay dividends.
What is Sagimet Biosciences, Inc. Class A’s EPS estimate?
Sagimet Biosciences, Inc. Class A’s EPS estimate is -0.42.
How many shares outstanding does Sagimet Biosciences, Inc. Class A have?
Sagimet Biosciences, Inc. Class A has 31,001,108 shares outstanding.
What happened to Sagimet Biosciences, Inc. Class A’s price movement after its last earnings report?
Sagimet Biosciences, Inc. Class A reported an EPS of -$0.4 in its last earnings report, missing expectations of -$0.386. Following the earnings report the stock price went down -12.245%.
Which hedge fund is a major shareholder of Sagimet Biosciences, Inc. Class A?
Currently, no hedge funds are holding shares in SGMT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sagimet Biosciences, Inc. Class A Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$28.57 (417.57% Upside)
$28.57 (417.57% Upside)
Blogger Sentiment
Bullish
SGMT Sentiment 66%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 1.0M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.6%
Last 30 Days ▲ 1.0%
Last 30 Days ▲ 1.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-0.89%
12-Months-Change
Fundamentals
Return on Equity
-39.78%
Trailing 12-Months
Asset Growth
-26.53%
Trailing 12-Months
Company Description
Sagimet Biosciences, Inc. Class A
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
SGMT Stock 12 Month Forecast
Average Price Target
$28.57
▲(417.57% Upside)
Technical Analysis
Codexis
―
Cabaletta Bio
―
Black Diamond Therapeutics
―
Atea Pharmaceuticals
―
Entrada Therapeutics Inc
―
Ownership Overview
10.06% Insiders
5.86% Mutual Funds
20.54% Other Institutional Investors
59.73% Public Companies and Individual Investors